Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852

Lung Cancer Research Foundation (merged with Free to Breathe)

participant Login


Working together on a global mission

  • October 25 2017

    Share |
    Working together on a global mission

    By Mary Henningfield, PhD, Director of Scientific Education and Research

    Free to Breathe (now merged with the Lung Cancer Research Foundation) is proud to be a member of the Global Lung Cancer Coalition (GLCC). Not only is lung cancer the number one cancer killer in the United States, but worldwide as well.

    The GLCC recently held a meeting in Tokyo, Japan, prior to the 18th World Conference on Lung Cancer (WCLC). The GLCC is the international “voice” of patients with lung cancer. Formed in 2001, the GLCC includes 37 patient organizations from 26 countries worldwide.

    A key initiative of GLCC is the creation of the e-atlas. This resource provides data on lung cancer incidence, mortality, survival and national policy for countries worldwide. GLCC also performs research, including a bibliometric study that looked at published studies to provide insights into research outputs. Lung cancer research represented only 5.6% of overall cancer research in 2013, a 1.2% increase since 2004. Of the 24 countries included in the study, the United States accounted for the most published research during the 10-year period evaluated. Approximately 20% of the articles focused on genetics and less than 1% focused on quality of life. Research on palliative care was also low.1 This work highlights the need for greater efforts to prioritize lung cancer research. The Lung Cancer Research Foundation will continue to fund innovative, high-reward research that might otherwise go uninvestigated. We fund both U.S. and international researchers of all experience levels with the goal of promoting innovation among a broad range of investigators.

    The WCLC in Yokohama, Japan, followed the GLCC meeting of the member organizations. The WCLC is solely focused on lung cancer research. Many attendees were excited to learn that the Presidential Symposium of the Top 3 Abstracts included important research into patient-reported outcomes in a clinical trial of an immunotherapy. The conference also had a special track for patient advocacy, including a joint session with the International Association for the Study of Lung Cancer and GLCC to discuss current issues in lung cancer advocacy. Presentations included topics such as the use of GLCC data, measuring value in healthcare, and accessing new lung cancer therapies in Latin America.

    1. Aggarwal A, Lewison G, Idir S, et al. The state of lung cancer research: A global analysis. J Thorac Oncol. 2016;11(7):1040-1050.



  1. Jennifer Olson 01:34pm, 10/26/2017

    Only 5.6% of research funding in spite of being deadlier than breast, colon and prostate combined?!

Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2018 Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.